NFL player teams with Sanofi on Auvi-Q promo; Judge backs Cubicin in patent fight with Hospira;

@FiercePharma: ICYMI: 20 Highest-Paid Biopharma CEOs of 2012. Feature Reactions? Use #FPexecpay. | Follow @FiercePharma

@EricPFierce: Women sue Apotex over manufacturing issues that led to too many placebos and unexpected pregnancies. More | Follow @EricPFierce

> Former NFL player Jerome "The Bus" Bettis has signed on with Sanofi ($SNY) to promote anaphylaxis awareness and the company's talking epinephrine injection pen, Auvi-Q. Report

> A federal judge refused to toss multidistrict litigation accusing Pfizer's ($PFE) King Pharmaceuticals unit and Mutual Pharmaceutical of conspiring to keep generic versions of the muscle relaxant Skelaxin off the market. Report

> A U.S. federal court backed Cubist's ($CBST) patent protection on its antibiotic Cubicin in the face of a challenge from generics producer Hospira ($HSP). Report

> Pfizer plans to keep 475 jobs in its consumer healthcare business at a New Jersey facility after moving about 400 staffers spun off with its Zoetis animal health business to a new location. Report

> British farmers will be first in line for a new Merck ($MRK) vaccine against Schmallenberg virus, to be used in sheep and cattle. Report

Medical Device News

@FierceMedDev: German cops seize Boston Scientific stents in cutthroat patent fight. More | Follow @FierceMedDev

@MarkHFierce: It's that time of year again: We're seeking nominations for this year's fiercest medical device and Dx companies. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic rode some international sales success to quarterly revenue growth. Article | Follow @DamianFierce

> Medtronic, J&J's Cordis headline EuroPCR 2013. Article

> Interleukin Genetics raises $12M in last-ditch save. DxExtra

> Sequester cuts threaten FDA's access to industry user fees. Story

Biotech News

@FierceBiotech: New special: Top 10 Biotech CEO Pay Packages of 2012 via @RyanMFierce and @EmilyMFierce. Report | Follow @FierceBiotech

@JohnCFierce: Bayer bolsters campaign for PAH drug riociguat with positive long-term data. More | Follow @JohnCFierce

@RyanMFierce: Interviewed Regeneron's Yancopoulos, biotech's highest paid exec in 2012, about promising allergy drug and success recipe. Story | Follow @RyanMFierce

> Novo nabs anti-infectives outfit in $700M buyout. More

> Pfizer picks up the pieces after its armed antibody crashes in PhIII. Article

> Analysts question Teva's blockbuster expectations on drug makeovers. Story

Biotech Research News

 @EmilyMFierce:  | Follow @EmilyMFierce

> Researchers pinpoint protein involved in cancer cell death. Item

> Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease. More

> Drug boosts effectiveness of radiation therapy for brain tumors. Story

> Scientists use cloning method to create embryonic stem cells. Article

Pharma Manufacturing News

> Novartis' Sandoz unit recalls products from U.S., Poland. News

> Chinese drugmaker fights counterfeiting in Africa with SMS technology. More

> Impax brings in big guns to get on top of manufacturing problems. Story

> Apotex sued over problems on contraceptive packaging line. Article

> Gorsky pleads with employees to think quality. More

And Finally... How pill bottles tattle on poor drug-takers. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.